跳至主要内容
临床试验/NL-OMON51654
NL-OMON51654
已完成
不适用

A Clinical Evaluation of the RheOx Bronchial Rheoplasty System for the Treatment of the Symptoms of Chronic Bronchitis in Adult Patients with COPD - The RheSolve Study

GALA therapeutics0 个研究点目标入组 15 人待定

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
未指定
发起方
GALA therapeutics
入组人数
15
状态
已完成
最后更新
2年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
2年前
研究类型
Interventional

研究者

发起方
GALA therapeutics

入排标准

入选标准

  • 1\. Patient is at least 35 years of age.
  • 2\. Patient has chronic bronchitis, defined as productive cough for three months
  • in each of two successive years, whereas other causes of productive cough have
  • been ruled out.
  • 3\. Patient has a CAT score \>\= 10\.
  • 4\. Patient has an SGRQ score \>\= 25\.
  • 5\. Patient\*s responses to the first two questions of the CAT instrument sum to
  • \>\= 7 points or the sum is 6 points and the patient\*s total CAT score is \> 20
  • 6\. Patient has FEV1/FVC \< 0\.7\.
  • 7\. Patient has a pre\-procedure post\-bronchodilator FEV1 percent predicted of \>\=

排除标准

  • 1\. Patient has known unresolved lower respiratory tract infection (e.g.,
  • pneumonia, mycobacterium avium\-intracellulare infection (MAI), fungus,
  • tuberculosis).
  • 2\. Patient has a steroid\-dependent condition requiring \>10 mg of oral
  • corticosteroid per day.
  • 3\. Patient has any implantable electronic device (e.g., pacemaker, cardioverter
  • defibrillator, neuro\-stimulation devices).
  • 4\. Patient has a history of arrhythmia within past two years which includes
  • tachy\-atrial arrhythmias, any ventricular tachy\-arrhythmias, or sinus
  • bradycardia with heart rate less than 45 beats per minute.

结局指标

主要结局

未指定

相似试验